



Europass Curriculum Vitae

Dichiarazione sostitutiva di certificazione e dell'atto di notorietà ai sensi degli artt. 46 e 47 e degli artt. 75 e 76 del DPR 445/2000 e successive modificazioni ed integrazioni.

La sottoscritta MICHELA ANSUINELLI, sotto la propria responsabilità, ai sensi e per gli effetti degli articoli 46 e 47 del DPR 445/2000, consapevole di quanto prescritto dagli articoli 75 e 76 del medesimo DPR, rispettivamente sulla responsabilità penale prevista per chi rende false dichiarazioni e sulla decadenza dai benefici eventualmente conseguenti al provvedimento emanato sulla base di dichiarazioni non veritiere,

Dichiara

Che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità.

Rome, January 11, 2023

Personal information

First name(s) /

Surname(s)

Address(es)

Telephone(s)

Michela Ansuinelli MD

Fax(es)

E-mail

Nationality

Italian

Date of birth

/

Gender

Female

Desired employment / Occupational field

RTD-A, Division of Hematology, Department Translational and Precision Medicine; 'Sapienza' University of Rome

Work experience

Dates

- **Jun 06, 2021- ongoing:** Research Fellow at Dana Farber Cancer Institute- Department of Medical Oncology, Boston (MA), USA.
- **Apr 19, 2019- May 15, 2021:** CAR-T Unit member- AOU Policlinico Umberto I, Rome, Italy.
- **Dec 14, 2019- May 15, 2021:** PhD student with clinical and research activity at Department Translational and Precision Medicine; 'Sapienza' University of Rome
- **Dec 12, 2014 – Dec 13, 2019:** Resident physician at Department Translational and Precision Medicine; 'Sapienza' University of Rome

Education and training

Dates

Title of qualification awarded
Principal subjects/occupational skills covered

Name and type of organisation providing education and training

Jun 06, 2021 - ongoing

Research Fellow

Research activity focused on immune-reconstitution after allogeneic stem cell transplantation and after CAR-T cell therapy

Dana Farber Cancer Institute - Department of Medical Oncology. Harvard Medical School

Dates

Title of qualification awarded
Principal subjects/occupational skills covered

Name and type of organisation providing education and training

Dic 14, 2019 - Ott 31, 2022

PhD student in *Innovation in immune-mediated and hematological disorders*

Clinical activity and translational research in acute lymphoblastic leukemias, lymphoproliferative disorders, CAR-T cells. Tutor: Prof.ssa Sabina Chiaretti

Department Translational and Precision Medicine; University of Rome 'Sapienza'

Dates

Title of qualification awarded

Name and type of organisation providing education and training

Aug 2018 - Nov 2018

Visiting physician

Immunotherapy and Platinum Inpatients service at SCCA-Fred Hutchinson- UW Medicine of Seattle

Dates

Title of qualification awarded
Principal subjects/occupational skills covered

Name and type of organisation providing education and training

Dec 12, 2014 - Dec 13, 2019

Residency: Specialization in Hematology

Lymphoproliferative disorders; Immunotherapies; CAR-T cells; allogeneic and autologous transplantation.

Thesis: Total Therapy strategy for adult patients with newly diagnosed Ph+ acute lymphoblastic leukemia: final results of the GIMEMA 1509 trial. Supervisor: Prof.ssa Sabina Chiaretti (70/70 with honors)

Department Translational and Precision Medicine; University of Rome 'Sapienza'

Dates
Title of qualification awarded

March 13, 2014
Registration at the general Medical Council of Rome, Italy. N. 0000060543

Dates
Title of qualification awarded

2007-2013
Degree in Medicine and Surgery

Thesis: Ruolo prognostico della PET/TC con 18-FDG nel linfoma diffuso a grandi cellule B primitivo del mediastino: risultati di uno studio prospettico, multicentrico, italiano su 125 pazienti. Supervisor: Prof. Maurizio Martelli (110/110 with honors)

Name and type of organisation providing education and training

Sapienza University of Rome

Dates
Title of qualification awarded

2011-2013
Medical student
Non-Hodgkin Lymphoma Clinic

Name and type of organisation providing education and training

Department Translational and Precision Medicine; University of Rome 'Sapienza'

Personal skills and competences

Mother tongue(s)

Italian

Other language(s)

English

Self-assessment

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
B2	B2	B2	B2	B2

European level

Computer skills and competences

Operating System: Microsoft Windows 10, macOS
Softwares: Word, Excel, Access, Powerpoint, Outlook, Epi-Info, R, RStudio, Flowjo, Cytobank, CellEngine

Driving licence

Italy B type

Additional information

Research Activities and Scientific Interests

- Research activities: I was trained on several laboratory techniques during my fellowship and PhD program such as: DNA and RNA extraction, qualitative PCR, ddPCR, next generation sequencing techniques (DNA-targeted sequencing and RNA-sequencing) applied to patients with acute lymphoblastic leukemia (ALL) either for the purpose of MRD monitoring and evaluation or to better understand the genomic complexity of the disease.

During the last year, at Dana Farber Cancer Institute, I focused my research on immune-reconstitution after allogeneic stem cell transplant and CAR-T cell therapy using flow cytometry, mass cytometry and TCR sequencing techniques.

From a clinical standpoint, I was involved mostly in the management of patients with ALL and of patients with indication for CAR-T cell therapy within the Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome.

- Sub-investigator in several retrospective and prospective studies focusing on ALL and CAR-T cell therapy.
- Member of the writing committee of the GIMEMA LAL2820 and GIMEMA LAL2922 clinical trials
- Teaching assistant (2018-2020): Hematology (Applied Pathology IV) Corso di Laurea "F" in Medicine and Surgery, Sapienza Università di Roma, Blood diseases

Contributions:

- Contributions to Ematologia in Progress (<https://www.ematologiainprogress.it>) on the chapters on ALL and CAR-T cells coordinated by Prof. Robin Foà.

Society memberships, Awards and Honors:

- Young Investigator Award winner granted by Adaptive Biotechnologies
- Junior member of the Italian Society of Hematology (SIE)
- Junior member of the European Hematology Association (EHA)

Bibliometric indexes:

- Scopus ID 57193093591. ORCID 0000-0002-3424-915X
- Total Impact Factor: 73.331
- Average Impact Factor: 4.889
- Total Citations: 132 (Scopus)
- Average Citations per Product: 8.8
- Hirsch (H) index: 6 (Scopus)

Co-author in peer-reviewed publications:

List of 12 publications selected for the evaluation.

1. Chiaretti S, Taherinasab A, Della Starza I, Canichella M, **Ansuinelli M**, De Propriis MS, Messina M, Spinelli O, Santoro A, De Novi LA, Cardinali D, Schipani M, Arena V, Bassan R, Guarini A, Foà R. ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings. *Leuk Lymphoma*. 2022 Dec 19:1-4.
2. Soscia R, Della Starza I, De Novi LA, Ilari C, **Ansuinelli M**, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, Cazzaniga G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases. *Hematol Oncol*. 2022 Oct 17.
3. Fazio F, Cunsolo G, Mancini F, De Propriis MS, Piciocchi A, Arena V, Messina M, **Ansuinelli M**, Taherinasab AT, Apicella V, Vitale A, Chiaretti S, Guarini A, Del Giudice I, Foà R. Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. *Leuk Lymphoma*. 2022 Jun;63(6):1512-1514.
4. **Ansuinelli M**, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, De Novi LA, Taherinasab A, Canichella M, Guarini A, Foà R, Chiaretti S. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. *Hematol Oncol*. 2021 Dec;39(5):680-686.
5. **Ansuinelli M**, Cesini L, Chiaretti S, Foà R. Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. *Expert Opin Emerg Drugs*. 2021 Sep;26(3):281-294.
6. Chiaretti S, **Ansuinelli M**, Vitale A, Elia L, Matarazzo M, Piciocchi A, Fazi P, Di Raimondo F, Santoro L, Fabbiano F, Califano C, Martinelli G, Ronco F, Ferrara F, Cascavilla N, Bigazzi C, Tedeschi A, Sica S, Di Renzo N, Melpignano A, Beltrami G, Vignetti M, Foà R. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. *Haematologica*. 2021 Jul 1;106(7):1828-1838.
7. Di Rocco A, Cuneo A, Di Rocco A, Merli F, De Luca G, Petrucci L, **Ansuinelli M**, Penna D, Rotondo F, Rigolin GM, Giaino M, Re F, Farcomeni A, Martelli M, Foà R. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. *Leuk Lymphoma*. 2021 Apr;62(4):828-836.
8. Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, **Ansuinelli M**, Elia L, Albertini Petroni G, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foà R. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. *Haematologica*. 2021 Jun 1;106(6):1559-1568.
9. Marchesi F, Capria S, Giannarelli D, Trisolini SM, **Ansuinelli M**, Caputo MD, Serrao A, Gumenyuk S, Renzi D, Pupo L, Palombi F, Provenzano I, Di Rocco A, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Cantonetti M, Mengarelli A. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. *Bone Marrow Transplant*. 2018 Aug;53(8):1051-1054.
10. Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, **Ansuinelli M**, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M,

Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL. Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). *Oncologist*. 2018 Sep;23(9):1033-1038

11. De Sanctis V, Alfò M, Di Rocco A, **Ansuinelli M**, Russo E, Osti MF, Valeriani M, Minniti G, Grapulin L, Musio D, Bracci S, Spagnoli A, Moleti ML, Tombolini V, Martelli M. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors. *Hematol Oncol*. 2017 Dec;35(4):554-560.
12. Di Rocco A, De Angelis F, **Ansuinelli M**, Foà R, Martelli M. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? *Expert Rev Hematol*. 2017 Sep;10(9):761-774.

Books/textbooks for the medical or scientific community:

- Chiaretti S, Guarini A, **Ansuinelli M**, De Propris S, Mancini F, Nardacci MG, Elia L, Cavalli M, De Novi AL, Apicella V, Di Rocco A, Vitale A, Delle Starza I, Foà R. Leucemia acuta linfoblastica dell'adulto. Eureka srl, 2020, pp 1-128. (Monografia)

INFORMATIVA AI SENSI DEL DECRETO LEGISLATIVO 30 GIUGNO 2003 N. 196 "CODICE IN MATERIA DI PROTEZIONE DEI DATI PERSONALI". LA SOTTOSCRITTA DICHIARA INOLTRE DI ESSERE INFORMATA, AI SENSI E PER GLI EFFETTI DALL'ART. 13 DEL D. LGS. 196/03 IVI COMPRESI I DIRITTI CHE, IN RELAZIONE AL TRATTAMENTO MANUALE/INFORMATIZZATO DEI SUOI DATI PERSONALI CUI QUI ESPRESSAMENTE SI ACCONSENTE, LE DERIVANO AI SENSI DELL'ART. 07 DELLA MEDESIMA LEGGE.
Rome, January 11, 2023

Firma